Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease
Open Access
- 20 September 2010
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 2 (3), 313-320
- https://doi.org/10.3390/pharmaceutics2030313
Abstract
Application of oral fast release amantadine and levodopa may induce an improvement of motor symptoms in patients with Parkinson’s disease (PD). The objective of this trial was to investigate the clinical efficacy of a fast release amantadine sulfate formulation on simple and complex movement performance and putative relations to the pharmacokinetic behavior in PD patients. We challenged two cohorts of 12 PD patients, who were taken off their regular antiparkinsonian treatment for at least 12 hours, with oral 300 mg amantadine sulfate. We scored motor symptoms and performed instrumental tasks, which ask for performance of simple or complex motion series under cued conditions. Motor symptoms and performance of complex movements significantly improved in contrast to the carrying-out of simple motions. N-methyl-D-aspartic acid antagonistic and dopaminomimetic amantadine also influences altered higher predominant prefrontal cognitive functions. Therefore, performance of complex motion series improved, whereas carrying-out of simple repetitive movements is more associated to the striatal dopamine dependent basal ganglia function.This publication has 10 references indexed in Scilit:
- Placebo influences on dyskinesia in Parkinson's diseaseMovement Disorders, 2008
- The biochemical bases of the placebo effectScience and Engineering Ethics, 2004
- Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.2004
- Simple movement sequences better correlate to levodopa plasma levels than complex onesJournal of Neural Transmission. Supplementum, 2004
- Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's diseaseNeuroscience Letters, 2003
- Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET [18F]-DOPA KiParkinsonism & Related Disorders, 2001
- The Functional Neuroanatomy and Long-Term Reproducibility of Brain Activation Associated with a Simple Finger Tapping Task in Older Healthy Volunteers: A Serial PET StudyNeuroImage, 2000
- Amantadine for Levodopa-Induced DyskinesiasArchives of Neurology, 1999
- Short-term effect of amantadine sulphate on motor performance and reaction time in patients with idiopathic Parkinson's diseaseJournal of Neural Transmission, 1999
- Image processing for the study of brain structure and function: problems and programsThe Journal of Neuropsychiatry and Clinical Neurosciences, 1992